Kane Biotech Inc. - Biotechnology Company Focused on Developing Applications and Products for their Biofilm Technology
SNNLive spoke with Mark Ahrens-Townsend, President and CEO of Kane Biotech Inc. (TSX-V: KNE) at The MicroCap Conference 2017 in New York City, NY.
Monday, October 30, 2017
Kane Biotech (TSX-V: KNE) is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, according to the Company’s website (see here: www.kanebiotech.com).
SNNLive spoke with Mark Ahrens-Townsend, President and CEO of Kane Biotech Inc. at The MicroCap Conference 2017 in New York City, NY, and they discuss the following topics:
- Overview and history of Kane Biotech Inc.
- Biofilm industry
- Clinical Development
- Kane Biotech’s competitive advantage
- Mr. Ahrens-Townsend’s background
- Growth drivers
For more information about Kane Biotech Inc., please visit: www.kanebiotech.com
The interview may contain forward-looking statements about Kane Biotech Inc. See Kane Biotech Inc.'s periodic filings with SEDAR for more complete information.
More Commentary
-
Tuesday, August 20, 2019Deep Yellow - Uranium Exploration and Development Company Provides Corporate Update, Strategy and Value Catalysts for 2019
-
Wednesday, July 17, 2019SenesTech, Inc. - Technology for Managing Animal Pest Populations Discusses Commercialization and Growth Drivers for 2019
-
Tuesday, July 09, 2019Tiziana Life Sciences - UK Biotechnology Company Focused on Discovery and Development of Molecules to Treat Human Disease in Oncology and Immunology
- See More >
